



PAXMAN
LEBANESE CLINICAL
STUDIES OF EFFICACY





Observational study of scalp cooling success using Paxman Scalp Cooling System in Lebanon (2012 -2013).

Results

Success of using the Paxman Scalp Cooling System on Lebanese patients was overwhelming.

The results show a great response to the medical system.


Overall scalp cooling had excellent results in 91.21% patients.





Results per hospital

This was the result of a similar trend shown across the majority of hospitals in Lebanon.



91.21%

overall scalp cooling had excellent results in patients.

The graph illustrates Mount Lebanon with the highest success rate of 55 (93%) patients showing a great response. Mount Lebanon hospital also had 6 patients receiving the multi-combinational therapy known as TAC, which produces a high incidence of CIA. However, all 6 patients had a great response to the Paxman Scalp Cooling System showing no signs of hair loss.

- 91 cancer patients were used for this study with a success of 91%.
- 6 of these patients were undergoing treatment with TAC, with all 6 showing no signs of hair loss.
- The severity of CIA has been reduced greatly by using the Paxman Scalp Cooling System, with only 5 patients out of 91 not responding well to head cooling.


LEBANESE STUDY OF EFFICACY

Drug regimen	Average number of sessions	Average post infusion cooling times (Hr)	Minimum recommended post infusion cooling time
Docetaxel 80-130mg as monotherapy or combination	4	2h 45	Excellent result
TAC (Docetaxel 100mg, Doxorubicin 70mg, Cyclophosphamide 1gr) administered 10 6 patients.	4	4h 45-5h 15	Excellent result, 31-year-old patient
AC (Doxorubicin 100mg /Endoxan 1000mg)	2-4	2h 15-4h 15	1 patient moved hospital after 2 cycles and lost her hair as cooling to the scalp was not offered
Taxotere 100mg + Herceptin	1-6	2h 45	Excellent result
Taxol 120-140mg	4-15	2h 45	1 patient did not continue after 2nd cycle, medium hair loss was observed
Taxol 120mg/Carboplatin	6	2h 45	Excellent results
FEC (5 Fluorouracil 850-900mg, Epirubicin 130-160mg, Cyclophosphamide 850-900mg)	2-3	4h 15-5h 15	Hair loss was observed at really high doses, excellent results at lower dose regimens
Alimta 700mg + Carboplatin 300mg	6	2h 45	Excellent results
FAC (5 Fluorouracil 750mg, Doxorubicin 60-70mg, Cyclophosphamide 750mg/ 1gr)	3-4	3h-4h 30	Excellent results
TCH (Docetaxel 100mg/ Carboplatin 450mg/ Herceptin 600mg)	4-8	2h 30-3h 45	Excellent results
VP 16 Etoposide	15	2h 30-3h	5 cycles of 3 sessions, no hair loss, excellent results
Taxol/Cisplatin, Herceptin (TCiH) (T100mg, Ci 150mg, H440mg)	4	2h 45	Excellent results
MTX 100mg - Doxorubicin 80mg	3	3h	Excellent results
AD (Doxorubicin 50mg, Dacarbazine 550mg)	6	2h 30	Excellent results
Gemzar 1600mg + Carboplatin	1-6	2h 45	Excellent results



Methods

- 91 cancer patients were used in this study.
- Open non-randomised observational study conducted in several Lebanon sites between March 2012–April 2013.



This study was carried out by Professor Fadi Nasr, consisting of more than 620 sessions, on various regimens and dosages (shown left).

Professor Fadi Nasr's study demonstrates the effectiveness of the Paxman Scalp Cooling System on a variety of anti-cancer treatments. It should be noted that the difference in climate, nature of skin and types of hair amongst European and Mediterranean, makes a difference with pre/post-infusion times.

Scalp cooling times:

- Study was carried out using both the European and US protocols.
- Post-infusion times with exact dosages were given to patients.
- Pre-infusion cooling time of 90 minutes.
- Cooling was maintained during the infusion period.
- Post-infusion cooling time was dependent upon drug dosage (120-360 minutes).



PAXMAN^o
PIONEERS IN SCALP COOLING